biotech firms expanding glp-1 use beyond diabetes and obesity 2025 therapeutics are no longer a GLP‑1 story — they're a global industrial strategy The Future of Obesity Treatment:

Nitrate enhances skeletal muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism

Tirzepatide is a GLP-1 receptor agonist that helps suppress appetite and is sold under the brand names Mounjaro and Zepbound

Frederiksen Y, Farver-Vestergaard I, Skovgrd NG, Ingerslev HJ, Zachariae R

CVS previously covered Zepbound until Lillys market rival Novo Nordisk struck a formulary access deal with the retail giant that kicked in on July 1 of last year and made Wegovy CVSs preferred treatment for obesity

Cleveland Clinic, 2021, Cellulite MedicalNewsToday, 2025, Does Ozempic affect the skin and muscle of your legs?